[Etanercept].
Mühlhäuser
U
U
Institut für Experimentelle und Klinische Pharmakologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
Münzel
F
F
Eschenhagen
T
T
D000293:Adolescent; D000328:Adult; D000368:Aged; D000818:Animals; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D016466:CHO Cells; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006224:Cricetinae; D003412:Cricetulus; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D010919:Placebos; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept